This Project Grant award in the amount of $559,874 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation. The award will fund research targeting genomic drivers of Hurthle cell thyroid cancer through the use of mTOR and eIF2 inhibition. The performance period for this grant is from September 30, 2024 to September 29, 2026. As a leading academic medical center and research institution, The Cleveland Clinic Foundation has a history of delivering a range of medical services and research support to federal agencies, including the Department of Veterans Affairs, Department of Defense, National Institutes of Health, and Centers for Disease Control and Prevention.
Generated 1/28/25, 7:28 AM